(1r-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt
Ecabet sodium
CAS: 86408-72-2
Molecular Formula: C20H27NaO5S
(1r-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt - Names and Identifiers
| Name | Ecabet sodium |
| Synonyms | Gastrom ta-2711 ECABET SODIUM Ecabet sodium Ecabetsodiumsalt (2R,4aS,10aS)-2,4a-dimethyl-7-(propan-2-yl)-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2-carboxylic acid 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, monosodium salt, (1R,4aS,10aR)- 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, monosodium salt, [1R-(1α,4aβ,10aα)]- (1R-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt (1r-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt |
| CAS | 86408-72-2 |
| EINECS | 1312995-182-4 |
| InChI | InChI=1/C20H28O5S/c1-12(2)15-9-13-5-6-14-11-19(3,18(21)22)7-8-20(14,4)16(13)10-17(15)26(23,24)25/h9-10,12,14H,5-8,11H2,1-4H3,(H,21,22)(H,23,24,25)/t14-,19+,20-/m0/s1 |
(1r-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt - Physico-chemical Properties
| Molecular Formula | C20H27NaO5S |
| Molar Mass | 402.48 |
| Density | 1.241g/cm3 |
| Melting Point | >300° |
| Specific Rotation(α) | D20 +59.4° (c = 0.5) |
| Storage Condition | Room Temprature |
| Refractive Index | 1.562 |
(1r-(1-alpha,4a-beta,10a-alpha))-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid sodium salt - Reference Information
| gastric mucosal protective agent | , it is listed as a reference preparation and a standard preparation by the Chinese listed drug list, and has anti-Helicobacter pylori effect that most anti-ulcer drugs do not have. Ecabet sodium can bind to the plasma protein of gastric mucosal lesions, cover the gastric mucosa, protect the gastric mucosa, and play a variety of pharmacological effects such as increasing the content of endogenous prostaglandins in the stomach. The results showed that the effective rate of ecabet sodium in the treatment of gastric ulcer and erosive gastritis was significantly higher than that of ranitidine, and the incidence of adverse reactions was significantly lower than that of ranitidine, which fully demonstrated the effectiveness and safety of ecabet sodium in the treatment of gastritis and gastric ulcer. It has been reported that in the process of eradication of Helicobacter pylori, conventional treatment combined with ecabet sodium can improve the eradication rate of Helicobacter pylori with good safety. The sales of digestive system chemicals in China's urban retail pharmacies increased from 26.5 billion yuan in 2015 to 32.62 billion yuan in 2018; the sales of digestive system Chinese patent medicines in China's urban retail pharmacies increased from 10.73 billion yuan in 2015 to 13.56 billion yuan in 2018.|
| Product characteristics | ecabet sodium is the biggest feature of "cover protection, direct treatment" cover protection dual efficacy. Ecabet sodium not only has the effect of binding with the plasma protein of the gastric mucosal lesion site, covering on the gastric mucosa, forming a membrane barrier, protecting the gastric mucosa, but also has the effect of inhibiting and killing Helicobacter pylori, quadruple therapy against Helicobacter pylori infection is widely used in clinic. It has high safety and high effectiveness, patients are very easy to accept, good medication compliance. |
| indication | 1. Apply to the following symptoms of gastric mucosal injury (erosion, bleeding, swelling, edema), acute gastritis, chronic gastritis in acute exacerbation. Gastric ulcer. |
| pharmacokinetic characteristics | after oral administration of ecabet sodium, gastrointestinal absorption rate was 3%~ 7%. Healthy adults oral ecabet sodium 1.0g,2~5 h up to the highest plasma drug concentration (about 1 μg · mL-1), half-life of about 8 h. Most of the drugs were excreted without metabolism, about 3% in urine and> 90% in feces within 72 h. |
| biological activity | Ecabet sodium (TA-2711) can be applied to some gastrointestinal diseases by inhibiting the production of ROS. Ecabet sodium can promote the eradication of Helicobacter pylori. Ecabet sodium reduced apoptosis. |
| Target | ROS production; Bacterial; Apotosis |
Last Update：2024-04-09 21:01:54
Supplier List
Product Name: Ecabet Sodium Visit Supplier Webpage Request for quotation
CAS: 86408-72-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 86408-72-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Ecabet Sodium Visit Supplier Webpage Request for quotation
CAS: 86408-72-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 86408-72-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History